Published in BMJ on February 15, 2003
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
SMP-1, a member of a new family of small myristoylated proteins in kinetoplastid parasites, is targeted to the flagellum membrane in Leishmania. Mol Biol Cell (2004) 1.95
Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93
Systems analysis of metabolism in the pathogenic trypanosomatid Leishmania major. Mol Syst Biol (2008) 1.49
Risk factors of visceral leishmaniasis in East Africa: a case-control study in Pokot territory of Kenya and Uganda. Int J Epidemiol (2008) 1.40
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Leishmaniasis. Postgrad Med J (2006) 1.23
Amiodarone destabilizes intracellular Ca2+ homeostasis and biosynthesis of sterols in Leishmania mexicana. Antimicrob Agents Chemother (2009) 1.14
Leishmaniasis. Postgrad Med J (2007) 1.13
Leishmania donovani and cutaneous leishmaniasis, Sri Lanka. Emerg Infect Dis (2007) 0.99
Synthetic sex pheromone attracts the leishmaniasis vector Lutzomyia longipalpis (Diptera: Psychodidae) to traps in the field. J Med Entomol (2009) 0.97
Evidence that intracellular stages of Leishmania major utilize amino sugars as a major carbon source. PLoS Pathog (2010) 0.97
Distribution and abundance of phlebotominae, vectors of leishmaniasis, in Argentina: spatial and temporal analysis at different scales. J Trop Med (2012) 0.96
Post-earthquake outbreak of cutaneous leishmaniasis in a rural region of southern Iran. Ann Trop Med Parasitol (2011) 0.94
Imported leishmaniasis in Germany 2001-2004: data of the SIMPID surveillance network. Eur J Clin Microbiol Infect Dis (2005) 0.93
Cyclic nucleotide specific phosphodiesterases of Leishmania major. BMC Microbiol (2006) 0.93
The biology and control of leishmaniasis vectors. J Glob Infect Dis (2010) 0.92
Synthetic sex pheromone attracts the leishmaniasis vector Lutzomyia longipalpis to experimental chicken sheds treated with insecticide. Parasit Vectors (2010) 0.91
Amastin peptide-binding antibodies as biomarkers of active human visceral leishmaniasis. Clin Vaccine Immunol (2006) 0.88
Serological screening confirms the re-emergence of canine leishmaniosis in urban and rural areas in Governador Valadares, Vale do Rio Doce, Minas Gerais, Brazil. Parasitol Res (2006) 0.87
Thrichomys laurentius (Rodentia; Echimyidae) as a putative reservoir of Leishmania infantum and L. braziliensis: patterns of experimental infection. PLoS Negl Trop Dis (2010) 0.86
The effect of removing potentially infectious dogs on the numbers of canine Leishmania infantum infections in an endemic area with high transmission rates. Am J Trop Med Hyg (2012) 0.86
Vector and reservoir control for preventing leishmaniasis. Cochrane Database Syst Rev (2015) 0.85
Regulation of gene expression in protozoa parasites. J Biomed Biotechnol (2010) 0.85
Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana. Antimicrob Agents Chemother (2005) 0.85
Antileishmanial activity and ultrastructural alterations of Leishmania (L.) chagasi treated with the calcium channel blocker nimodipine. Parasitol Res (2009) 0.84
Leishmania chagasi T-cell antigens identified through a double library screen. Infect Immun (2006) 0.83
Pentalinon andrieuxii root extract is effective in the topical treatment of cutaneous leishmaniasis caused by Leishmania mexicana. Phytother Res (2013) 0.83
Synthesis and antileishmanial activities of novel 3-substituted quinolines. Antimicrob Agents Chemother (2005) 0.82
Control of sand flies with attractive toxic sugar baits (ATSB) and potential impact on non-target organisms in Morocco. Parasit Vectors (2015) 0.80
Probing the structure of Leishmania donovani chagasi DHFR-TS: comparative protein modeling and protein-ligand interaction studies. J Mol Model (2010) 0.79
rK39 antigen for the diagnosis of visceral leishmaniasis by using human saliva. Am J Trop Med Hyg (2012) 0.79
Immunodominant antigens of Leishmania chagasi associated with protection against human visceral leishmaniasis. PLoS Negl Trop Dis (2012) 0.78
Elimination of visceral leishmaniasis on the Indian subcontinent. Lancet Infect Dis (2016) 0.78
Oral azithromycin versus its combination with miltefosine for the treatment of experimental Old World cutaneous leishmaniasis. J Parasit Dis (2014) 0.77
Intracellular Survival of Leishmania major Depends on Uptake and Degradation of Extracellular Matrix Glycosaminoglycans by Macrophages. PLoS Pathog (2015) 0.77
Study on natural breeding sites of sand flies (Diptera: Phlebotominae) in areas of Leishmania transmission in Colombia. Parasit Vectors (2015) 0.77
Specific and nonhomologous isofunctional enzymes of the genetic information processing pathways as potential therapeutical targets for tritryps. Enzyme Res (2011) 0.76
Leishmaniasis also occurs in Mediterranean countries. BMJ (2003) 0.75
Repellent effects of the essential oils of Cymbopogon citratus and Tagetes minuta on the sandfly, Phlebotomus duboscqi. BMC Res Notes (2017) 0.75
Multi-modal analysis of courtship behaviour in the old world leishmaniasis vector Phlebotomus argentipes. PLoS Negl Trop Dis (2014) 0.75
Probing elongating and branching β-D-galactosyltransferase activities in Leishmania parasites by making use of synthetic phosphoglycans. ACS Chem Biol (2011) 0.75
β-Nitrostyrenes as Potential Anti-leishmanial Agents. Front Microbiol (2016) 0.75
Telehealth: a perspective approach for visceral leishmaniasis (kala-azar) control in India. Pathog Glob Health (2012) 0.75
TNF signalling drives expansion of bone marrow CD4+ T cells responsible for HSC exhaustion in experimental visceral leishmaniasis. PLoS Pathog (2017) 0.75
Tropical Diseases on Insurgence: Clinician's Perspective. Indian J Dermatol (2017) 0.75
Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis. N Engl J Med (1999) 5.02
Failure of pentavalent antimony in visceral leishmaniasis in India: report from the center of the Indian epidemic. Clin Infect Dis (2000) 3.72
Rapid accurate field diagnosis of Indian visceral leishmaniasis. Lancet (1998) 3.55
Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med (2002) 2.97
Leishmaniasis: current status of vaccine development. Clin Microbiol Rev (2001) 2.62
CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. J Immunol (2002) 2.16
Randomised controlled trial of aminosidine (paromomycin) v sodium stibogluconate for treating visceral leishmaniasis in North Bihar, India. BMJ (1998) 2.15
Factors associated with visceral leishmaniasis in Nepal: bed-net use is strongly protective. Am J Trop Med Hyg (2001) 2.09
Diagnosing visceral leishmaniasis with the recombinant K39 strip test: experience from the Sudan. Trop Med Int Health (2001) 2.08
Studies on control of visceral leishmaniasis: impact of dog control on canine and human visceral leishmaniasis in Jacobina, Bahia, Brazil. Am J Trop Med Hyg (1998) 1.99
Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan. Lancet (2000) 1.86
Effect of insecticide-impregnated dog collars on incidence of zoonotic visceral leishmaniasis in Iranian children: a matched-cluster randomised trial. Lancet (2002) 1.66
A randomized controlled trial of insecticide-treated bednets and chaddars or top sheets, and residual spraying of interior rooms for the prevention of cutaneous leishmaniasis in Kabul, Afghanistan. Trans R Soc Trop Med Hyg (2000) 1.58
Latex agglutination test for the detection of urinary antigens in visceral leishmaniasis. Acta Trop (2001) 1.57
Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis (2001) 1.53
Treatment of Indian visceral leishmaniasis with single or daily infusions of low dose liposomal amphotericin B: randomised trial. BMJ (2001) 1.50
Protective immunity using recombinant human IL-12 and alum as adjuvants in a primate model of cutaneous leishmaniasis. J Immunol (1999) 1.47
Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun (2001) 1.47
Treatment of American cutaneous leishmaniasis with miltefosine, an oral agent. Clin Infect Dis (2001) 1.41
Rapid detection of Leishmania infantum infection in dogs: comparative study using an immunochromatographic dipstick test, enzyme-linked immunosorbent assay, and PCR. J Clin Microbiol (2002) 1.40
Spraying houses in the Peruvian Andes with lambda-cyhalothrin protects residents against cutaneous leishmaniasis. Trans R Soc Trop Med Hyg (2001) 1.31
Diagnosis of infections with Leishmania infantum using PCR-ELISA. Parasitology (2001) 1.12
An update on antileishmanial vaccine candidates and prospects for a canine Leishmania vaccine. Vet Parasitol (2001) 1.02
Incidence of and risk factors for symptomatic visceral leishmaniasis among human immunodeficiency virus type 1-infected patients from Spain in the era of highly active antiretroviral therapy. J Clin Microbiol (2002) 0.99
Topical insecticide treatments to protect dogs from sand fly vectors of leishmaniasis. Emerg Infect Dis (2001) 0.93
Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol (2007) 7.36
Drug resistance in leishmaniasis. Clin Microbiol Rev (2006) 7.35
Visceral leishmaniasis: current status of control, diagnosis, and treatment, and a proposed research and development agenda. Lancet Infect Dis (2002) 7.17
Antimalarial drug discovery: efficacy models for compound screening. Nat Rev Drug Discov (2004) 3.90
Structure-activity relationships of antileishmanial and antimalarial chalcones. Bioorg Med Chem (2003) 3.21
Splenic accumulation of IL-10 mRNA in T cells distinct from CD4+CD25+ (Foxp3) regulatory T cells in human visceral leishmaniasis. J Exp Med (2007) 2.75
Phase 4 trial of miltefosine for the treatment of Indian visceral leishmaniasis. J Infect Dis (2007) 2.74
Visceral leishmaniasis elimination programme in India, Bangladesh, and Nepal: reshaping the case finding/case management strategy. PLoS Negl Trop Dis (2009) 2.56
Longlasting insecticidal nets for prevention of Leishmania donovani infection in India and Nepal: paired cluster randomised trial. BMJ (2010) 2.30
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance. Genome Res (2011) 2.21
Visceral leishmaniasis: elimination with existing interventions. Lancet Infect Dis (2011) 2.19
Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin Infect Dis (2006) 2.17
High incidence of zidovudine induced anaemia in HIV infected patients in eastern India. Indian J Med Res (2010) 2.11
Artemisone--a highly active antimalarial drug of the artemisinin class. Angew Chem Int Ed Engl (2006) 2.09
Treatment options for visceral leishmaniasis: a systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis (2005) 2.06
Virgin soil: the spread of visceral leishmaniasis into Uttar Pradesh, India. Am J Trop Med Hyg (2005) 1.96
Diagnosis of visceral leishmaniasis. Trans R Soc Trop Med Hyg (2010) 1.93
Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine). Int J Antimicrob Agents (2003) 1.83
Highly antimalaria-active artemisinin derivatives: biological activity does not correlate with chemical reactivity. Angew Chem Int Ed Engl (2004) 1.80
Drug uptake and modulation of drug resistance in Leishmania by an aquaglyceroporin. J Biol Chem (2004) 1.79
Management of trypanosomiasis and leishmaniasis. Br Med Bull (2012) 1.78
Effectiveness and feasibility of active and passive case detection in the visceral leishmaniasis elimination initiative in India, Bangladesh, and Nepal. Am J Trop Med Hyg (2010) 1.74
Incidence of symptomatic and asymptomatic Leishmania donovani infections in high-endemic foci in India and Nepal: a prospective study. PLoS Negl Trop Dis (2011) 1.67
Sensitivities of Leishmania species to hexadecylphosphocholine (miltefosine), ET-18-OCH(3) (edelfosine) and amphotericin B. Acta Trop (2002) 1.64
Visceral leishmaniasis in the Indian subcontinent: modelling epidemiology and control. PLoS Negl Trop Dis (2011) 1.64
Vector control by insecticide-treated nets in the fight against visceral leishmaniasis in the Indian subcontinent, what is the evidence? Trop Med Int Health (2008) 1.63
Effect of village-wide use of long-lasting insecticidal nets on visceral Leishmaniasis vectors in India and Nepal: a cluster randomized trial. PLoS Negl Trop Dis (2010) 1.61
Implementation research to support the initiative on the elimination of kala azar from Bangladesh, India and Nepal--the challenges for diagnosis and treatment. Trop Med Int Health (2008) 1.59
A global comparative evaluation of commercial immunochromatographic rapid diagnostic tests for visceral leishmaniasis. Clin Infect Dis (2012) 1.59
Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist Updat (2006) 1.58
Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci Transl Med (2014) 1.57
Endocrine changes in male HIV patients. J Assoc Physicians India (2011) 1.56
Drug resistance in leishmaniasis. J Glob Infect Dis (2010) 1.52
Molecular mechanisms of antimony resistance in Leishmania. J Med Microbiol (2007) 1.50
Multilocus microsatellite typing (MLMT) reveals genetic homogeneity of Leishmania donovani strains in the Indian subcontinent. Infect Genet Evol (2008) 1.49
Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol (2011) 1.48
Identification of genetic markers in sodium antimony gluconate (SAG) sensitive and resistant Indian clinical isolates of Leishmania donovani through amplified fragment length polymorphism (AFLP). Acta Trop (2009) 1.47
Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India. Clin Infect Dis (2003) 1.46
In vitro and in vivo interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother (2006) 1.46
IL-27 and IL-21 are associated with T cell IL-10 responses in human visceral leishmaniasis. J Immunol (2011) 1.44
Options for active case detection of visceral leishmaniasis in endemic districts of India, Nepal and Bangladesh, comparing yield, feasibility and costs. PLoS Negl Trop Dis (2011) 1.42
Knowledge, attitude, and practices related to Kala-azar in a rural area of Bihar state, India. Am J Trop Med Hyg (2006) 1.40
Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents (2007) 1.39
The sensitivity of clinical isolates of Leishmania from Peru and Nepal to miltefosine. Am J Trop Med Hyg (2005) 1.36
A proteomics screen implicates HSP83 and a small kinetoplastid calpain-related protein in drug resistance in Leishmania donovani clinical field isolates by modulating drug-induced programmed cell death. Mol Cell Proteomics (2006) 1.36
Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models. Parasitol Res (2005) 1.36
Cost-effectiveness analysis of combination therapies for visceral leishmaniasis in the Indian subcontinent. PLoS Negl Trop Dis (2010) 1.35
Costs of patient management of visceral leishmaniasis in Muzaffarpur, Bihar, India. Trop Med Int Health (2006) 1.35
Longitudinal seroepidemiologic study of visceral leishmaniasis in hyperendemic regions of Bihar, India. Am J Trop Med Hyg (2009) 1.34
Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - an experience of a tertiary care hospital in Varanasi (India). BMC Gastroenterol (2008) 1.34
Diarrhea, CD4 counts and enteric infections in a hospital - based cohort of HIV-infected patients around Varanasi, India. BMC Infect Dis (2006) 1.33
IL-10 neutralization promotes parasite clearance in splenic aspirate cells from patients with visceral leishmaniasis. J Infect Dis (2011) 1.33
The epidemiology of Leishmania donovani infection in high transmission foci in India. Trop Med Int Health (2010) 1.30
Measurement of recent exposure to Phlebotomus argentipes, the vector of Indian visceral Leishmaniasis, by using human antibody responses to sand fly saliva. Am J Trop Med Hyg (2010) 1.30
Characterization of natural antimony resistance in Leishmania donovani isolates. Am J Trop Med Hyg (2007) 1.29
Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis. PLoS Negl Trop Dis (2012) 1.27
Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother (2008) 1.26
In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent. J Antimicrob Chemother (2010) 1.23
Evaluation of leishmanin skin test in Indian visceral leishmaniasis. Am J Trop Med Hyg (2009) 1.22
IL-7-producing stromal cells are critical for lymph node remodeling. Blood (2012) 1.22
Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: chemical library screen and antileishmanial activity. Antimicrob Agents Chemother (2004) 1.21
Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo. J Med Chem (2004) 1.21
Consultative meeting to develop a strategy for treatment of cutaneous leishmaniasis. Institute Pasteur, Paris. 13-15 June, 2006. Kinetoplastid Biol Dis (2007) 1.20
Reassessment of immune correlates in human visceral leishmaniasis as defined by cytokine release in whole blood. Clin Vaccine Immunol (2012) 1.20
Targeted killing of Leishmania donovani in vivo and in vitro with amphotericin B attached to functionalized carbon nanotubes. J Antimicrob Chemother (2011) 1.19
Case study for a vaccine against leishmaniasis. Vaccine (2013) 1.19
Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag (2007) 1.17
Topical treatment for cutaneous leishmaniasis. Curr Opin Investig Drugs (2002) 1.17
A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am J Trop Med Hyg (2005) 1.17
Persistence of Leishmania donovani antibodies in past visceral leishmaniasis cases in India. Clin Vaccine Immunol (2010) 1.16
Latent infection with Leishmania donovani in highly endemic villages in Bihar, India. PLoS Negl Trop Dis (2013) 1.16
Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Trop (2007) 1.16
Common variants in the HLA-DRB1-HLA-DQA1 HLA class II region are associated with susceptibility to visceral leishmaniasis. Nat Genet (2013) 1.15
Inhibition of ABC transporters abolishes antimony resistance in Leishmania Infection. Antimicrob Agents Chemother (2007) 1.15
In vivo activities of farnesyl pyrophosphate synthase inhibitors against Leishmania donovani and Toxoplasma gondii. Antimicrob Agents Chemother (2002) 1.14
Diagnosis of Indian visceral leishmaniasis by nucleic acid detection using PCR. PLoS One (2011) 1.14
A multiattribute utility evaluation of different methods for the detection of enteric protozoa causing diarrhea in AIDS patients. BMC Microbiol (2010) 1.13
Evaluation of blood agar microtiter plates for culturing leishmania parasites to titrate parasite burden in spleen and peripheral blood of patients with visceral leishmaniasis. J Clin Microbiol (2010) 1.13
A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis. Vaccine (2011) 1.13
Population preference of net texture prior to bed net trial in Kala-Azar-endemic areas. PLoS Negl Trop Dis (2007) 1.13
Azasterols as inhibitors of sterol 24-methyltransferase in Leishmania species and Trypanosoma cruzi. J Med Chem (2003) 1.12
Use of Leishmania donovani field isolates expressing the luciferase reporter gene in in vitro drug screening. Antimicrob Agents Chemother (2005) 1.12
Novel azasterols as potential agents for treatment of leishmaniasis and trypanosomiasis. Antimicrob Agents Chemother (2004) 1.12
Study of parasite kinetics with antileishmanial drugs using real-time quantitative PCR in Indian visceral leishmaniasis. J Antimicrob Chemother (2011) 1.11
Interferon-gamma release assay (modified QuantiFERON) as a potential marker of infection for Leishmania donovani, a proof of concept study. PLoS Negl Trop Dis (2011) 1.11
Activity of bisphosphonates against Trypanosoma brucei rhodesiense. J Med Chem (2002) 1.11
Characterisation of antimony-resistant Leishmania donovani isolates: biochemical and biophysical studies and interaction with host cells. Int J Parasitol (2011) 1.10
Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India. Infect Genet Evol (2010) 1.09
Deletion of IL-4Ralpha on CD4 T cells renders BALB/c mice resistant to Leishmania major infection. PLoS Pathog (2007) 1.09
Serological markers of sand fly exposure to evaluate insecticidal nets against visceral leishmaniasis in India and Nepal: a cluster-randomized trial. PLoS Negl Trop Dis (2011) 1.08
Mapping the antigenicity of the parasites in Leishmania donovani infection by proteome serology. PLoS One (2006) 1.08
Antiparasitic activities and toxicities of individual enantiomers of the 8-aminoquinoline 8-[(4-amino-1-methylbutyl)amino]-6-methoxy-4-methyl-5-[3,4-dichlorophenoxy]quinoline succinate. Antimicrob Agents Chemother (2008) 1.07
Asymptomatic Leishmania infection: a new challenge for Leishmania control. Clin Infect Dis (2014) 1.07
Antimony-resistant but not antimony-sensitive Leishmania donovani up-regulates host IL-10 to overexpress multidrug-resistant protein 1. Proc Natl Acad Sci U S A (2013) 1.07
CD8 T cell exhaustion in human visceral leishmaniasis. J Infect Dis (2013) 1.06